All-trans Retinoic Acid Enhances PARP Inhibitor Sensitivity After Cisplatin in Epithelial Ovarian Cancer

Study Background and Research Question

Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy, ranking as the fifth leading cause of cancer-related death in women worldwide. The standard first-line therapy combines maximal cytoreductive surgery with platinum-based chemotherapeutic agents, such as cisplatin (CDDP). Although this approach initially yields high response rates, most EOC tumors eventually recur, with only 20–40% of patients surviving five years post-diagnosis due to the emergence of chemoresistance. In recent years, poly(ADP-ribose) polymerase inhibitors (PARPi) have significantly improved outcomes for EOC patients, particularly those with BRCA1/2 mutations or homologous recombination deficiency (HRD). However, resistance to PARP inhibitors arises almost inevitably, especially following platinum-based chemotherapy. The central research question addressed by the reference study is whether all-trans retinoic acid (ATRA) can overcome PARPi resistance induced by prior cisplatin exposure in EOC.

Key Innovation from the Reference Study

The study's primary innovation lies in uncovering a mechanistic link between cisplatin-induced PARPi resistance and upregulation of a gene signature involving aldehyde dehydrogenase 1 family member A1 (ALDH1A1), nicotinamide phosphoribosyltransferase (NAMPT), PARP1, and checkpoint kinase 1 (CHEK1). High intracellular NAD+ levels, resulting from NAMPT upregulation, further drive PARP1 and ALDH1A1 activity, contributing to resistance. The research demonstrates that ATRA, a clinically approved agent, can downregulate these resistance-associated genes and reduce NAD+ levels, thereby sensitizing EOC cells to PARPi after cisplatin exposure.

Methods and Experimental Design Insights

To model clinically relevant resistance, the authors exposed EOC cell lines to cisplatin, followed by PARP inhibitor (niraparib) treatment. Both in vitro (cell proliferation, clonogenic survival) and in vivo (mouse xenograft) assays were used to assess the impact of ATRA on PARPi-resistant, cisplatin-pretreated EOC. Molecular analyses included RNA and protein quantification of ALDH1A1, NAMPT, PARP1, and CHEK1, as well as intracellular NAD+ measurements. The study also evaluated changes in cell viability and tumor growth in response to combination therapies.

Protocol Parameters

• Cisplatin exposure: EOC cells were pretreated with cisplatin to induce PARPi resistance before subsequent drug interventions.
• ATRA treatment: Clinically relevant concentrations of ATRA were administered both in vitro and in vivo prior to or alongside PARP inhibitor therapy.
• PARP inhibitor maintenance: Niraparib was used as the PARPi in maintenance regimens following cisplatin and/or ATRA treatment in murine EOC xenograft models.
• Molecular profiling: Quantitative PCR and Western blot analyses for ALDH1A1, NAMPT, PARP1, and CHEK1; NAD+ levels measured enzymatically.
• Functional assays: Cell proliferation and colony formation assays to assess drug sensitivity; tumor volume and survival analysis in mice.

Core Findings and Why They Matter

The study found that cisplatin pre-exposure induced a robust, PARPi-resistant phenotype in EOC cells, characterized by increased expression of ALDH1A1, NAMPT, PARP1, and CHEK1, as well as elevated NAD+ levels. This signature correlated with heightened enzymatic activity of ALDH1A1 and PARP1. Notably, ATRA treatment reversed these molecular changes, reducing both gene expression and NAD+ content. In both cell culture and animal models, the combination of ATRA and PARPi (niraparib) led to significant tumor growth inhibition and improved survival compared to PARPi alone after cisplatin exposure. These findings suggest that ATRA can resensitize EOC cells to PARP inhibition by targeting resistance mechanisms linked to NAD+ metabolism and DNA repair.

Comparison with Existing Internal Articles

The mechanistic focus on NAMPT and NAD+ metabolism in the reference study resonates with several established workflows in hematologic cancer research. For example, internal articles such as “FK866 (APO866): NAMPT Inhibitor Advancements in Hematologic Cancer” and “FK866 (APO866): Precision NAMPT Inhibition for Reliable Hematologic Studies” highlight the utility of targeting NAMPT to modulate NAD+ levels, induce caspase-independent cell death, and disrupt mitochondrial membrane integrity. While these internal resources focus on acute myeloid leukemia (AML) and related hematologic malignancies, the current study extends the paradigm to solid tumors—specifically, EOC—demonstrating that NAMPT and NAD+ modulation are broadly relevant resistance mechanisms across cancer types. This cross-domain connection underscores the translational value of NAMPT-targeting strategies, such as those enabled by FK866 (APO866), in overcoming therapy resistance beyond hematologic settings.

Limitations and Transferability

Despite its strengths, the study is limited by its reliance on preclinical models. While xenograft experiments provide valuable in vivo proof-of-concept, the clinical efficacy and safety of combining ATRA with PARP inhibitors in EOC patients, particularly following cisplatin-based therapies, remain to be established. The molecular signature of resistance may also vary among patient subgroups, and the long-term effects of NAD+ depletion in non-cancerous tissues require further investigation. Additionally, while the study implicates NAMPT and NAD+ as central resistance drivers, it does not fully explore potential compensatory pathways that may emerge with prolonged NAMPT inhibition.

Why this cross-domain matters, maturity, and limitations

The convergence of findings in ovarian and hematologic cancer models suggests that NAD+ metabolism—specifically, NAMPT activity—is a critical node in regulating drug resistance and tumor survival. The translation of NAMPT-centered approaches from leukemia to EOC reflects the maturity of this mechanistic insight, but also highlights the need for cancer-specific optimization and toxicity evaluation. As both fields advance, integrating metabolic inhibitors with established cytotoxic and targeted agents may offer synergistic benefits, but requires careful titration and biomarker-driven patient selection.

Research Support Resources

For researchers interested in investigating NAD+ metabolism modulation, FK866 (APO866) (SKU A4381) offers a highly specific, non-competitive NAMPT inhibition tool validated in both hematologic and solid tumor models. Its capacity to deplete NAD+ and induce caspase-independent cell death, as described in internal articles and product documentation, makes it suitable for exploring mechanisms similar to those identified in this EOC study. FK866 is available from APExBIO and can be solubilized in DMSO or ethanol according to experimental needs. For protocol guidance and troubleshooting, refer to the cited internal resources on AML and metabolic pathway targeting.